市場調査レポート
商品コード
1429511

iPS細胞(人工多能性幹細胞)の世界市場レポート 2024

Induced Pluripotent Stem Cell (iPSC) Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.36円
iPS細胞(人工多能性幹細胞)の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

iPS細胞(人工多能性幹細胞)の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には10.0%の年間複合成長率(CAGR)で48億1,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、慢性疾患の有病率の増加、ゲノムプロジェクトの拡大、iPS細胞由来の疾患モデル開発の進歩、遺伝性疾患の有病率の上昇、政府の取り組み、および急速な感染症の増加に起因すると考えられます。予測期間中に予想される主な動向には、パーキンソン病(PD)用の多能性幹細胞の開発、戦略的提携とパートナーシップ、iPS細胞由来NK細胞の作製、細胞治療用のiPS細胞(人工多能性幹細胞)の開発、重要な技術が含まれます。再生医療の研究開発、iPS細胞増殖培地の配合、個別化iPS細胞の作製、I型糖尿病向けの多能性幹細胞の開発への投資などが挙げられます。

iPS細胞(人工多能性幹細胞)市場は、主に慢性疾患の有病率の増加により大幅な成長を遂げています。心臓病、がん、脳卒中、糖尿病などの疾患は、あらゆる組織源から取得され、胚性幹細胞を模倣するように遺伝子組み換えされた人工多能性幹細胞に治療手段が見出されます。慢性障害と闘うパートナーシップ(PFCD)の報告書によると、調査対象となった1億3,300万人のアメリカ人のうち45%が少なくとも1つの慢性障害を抱えていました。同報告書はまた、米国の死亡10人中7人、約170万人が慢性疾患によるものと推定しており、人工多能性幹細胞治療の潜在的な影響を強調しています。慢性疾患の発生率の上昇は、人工多能性幹細胞治療市場における需要増加の主な要因です。

iPS細胞(人工多能性幹細胞)市場の成長に貢献しているのは、神経疾患の有病率の増加です。神経系に影響を与えるこれらの障害には、急性脊髄損傷、アルツハイマー病、筋萎縮性側索硬化症(ALS)などの症状が含まれます。多能性幹細胞は、疾患メカニズムの研究、薬物試験の実施、パーキンソン病やアルツハイマー病などの神経疾患の再生治療の進歩のための貴重なプラットフォームを提供します。たとえば、アルツハイマー病協会によると、2023年には65歳以上のアメリカ人670万人がアルツハイマー病になると推定され、2050年までに1,270万人に達すると予測されています。この神経疾患の増加傾向は、iPS細胞(人工多能性幹細胞)市場の重要な推進力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界のiPS細胞(人工多能性幹細胞)市場、由来細胞タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 肝細胞
  • 線維芽細胞
  • ケラチノサイト
  • 羊膜細胞
  • その他の派生細胞
  • 世界のiPS細胞(人工多能性幹細胞)市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 学術研究
  • 医薬品開発・創薬
  • 毒性スクリーニング
  • 再生医療
  • 世界のiPS細胞(人工多能性幹細胞)市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 研究

第7章 地域および国の分析

  • 世界のiPS細胞(人工多能性幹細胞)市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のiPS細胞(人工多能性幹細胞)市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • iPS細胞(人工多能性幹細胞)市場の競合情勢
  • iPS細胞(人工多能性幹細胞)市場企業プロファイル
    • FUJIFILM Holdings Corporation(FUJIFILM Cellular Dynamics, Inc)
    • Thermo Fisher Scientific, Inc
    • Takara Bio, Inc
    • Lonza Group AG
    • Astellas Pharma Inc

第31章 その他の大手および革新的な企業

  • ViaCyte, Inc
  • Ncardia
  • REPROCELL USA, Inc
  • Japan Tissue Engineering Co., Ltd
  • Merck KGaA
  • Cynata Therapeutics Limited
  • Dainippon Sumitomo Pharma
  • Shenzhen Bioscience
  • Shanghai Cell Therapy Group
  • Car-T Bio
  • JW therapeutics
  • Fosun Kite Biotechnology
  • Shanghai UniCar Therapy
  • Takaria Bio
  • SEED Biosciences SA

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14482

Induced pluripotent stem cells represent a regenerated form of stem cells, generated from existing adult cells, including hepatocytes, fibroblasts, keratinocytes, and neurons.

The principal derived cell types from induced pluripotent cells include hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. Hepatocytes, as the liver's primary functional cells, play a crucial role in an extensive range of metabolic, endocrine, and secretory functions. These cells find applications in various fields such as academic research, drug development and discovery, toxicity screening, and regenerative medicine, and are utilized in sectors including hospitals and research laboratories.

The induced pluripotent stem cell (iPSC) market research report is one of a series of new reports from The Business Research Company that provides induced pluripotent stem cell (iPSC) market statistics, including induced pluripotent stem cell (iPSC) industry global market size, regional shares, competitors with an induced pluripotent stem cell (iPSC) market share, detailed induced pluripotent stem cell (iPSC) market segments, market trends and opportunities, and any further data you may need to thrive in the induced pluripotent stem cell (iPSC) industry. This induced pluripotent stem cell (iPSC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The induced pluripotent stem cell (ipsc) market size has grown rapidly in recent years. It will grow from $2.97 billion in 2023 to $3.29 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The expansion observed in the historical period can be attributed to the increasing healthcare expenditure, a surge in funding, growing awareness of the medicinal potential of stem cell products, the utilization of induced pluripotent stem cell (iPSC) based drug discovery, a rising demand for personalized medicine, and the cost-effective benefits of iPSC for drug discovery.

The induced pluripotent stem cell (ipsc) market size is expected to see rapid growth in the next few years. It will grow to $4.81 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The anticipated growth in the forecast period can be attributed to the increasing prevalence of chronic diseases, the expansion of genomic projects, advancements in the development of iPSC-derived disease models, a rise in the prevalence of genetic diseases, government initiatives, and a rapid increase in technology. Major trends expected in the forecast period encompass the development of pluripotent stem cells for Parkinson's disease (PD), strategic collaborations and partnerships, the creation of iPSC-derived NK cells, the development of induced pluripotent stem cells (iPSC) for cell therapy, significant investment in regenerative medicine research and development, the formulation of iPSC expansion mediums, the creation of personalized iPSC, and the development of pluripotent stem cells for Type I diabetes.

The induced pluripotent stem cell market is witnessing significant growth, driven primarily by the increasing prevalence of chronic disorders. Conditions such as heart disease, cancer, stroke, and diabetes find treatment avenues in induced pluripotent stem cells, which are obtained from any tissue source and genetically modified to emulate embryonic stem cells. According to a report by the Partnership to Fight Chronic Disorder (PFCD), 45% of the 133 million Americans surveyed had at least one chronic disorder. The report also estimates that 7 out of 10 deaths in the USA, approximately 1.7 million, result from chronic disorders, emphasizing the potential impact of induced pluripotent stem cell treatment. The rising incidence of chronic diseases is a key driver for the increasing demand in the induced pluripotent stem cell treatment market.

Contributing to the growth of the induced pluripotent stem cell market is the escalating prevalence of neurological disorders. These disorders, affecting the nervous system, encompass conditions such as acute spinal cord injury, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS). Pluripotent stem cells offer a valuable platform for studying disease mechanisms, conducting drug testing, and advancing regenerative therapies for neurological conditions such as Parkinson's and Alzheimer's disease. For instance, according to the Alzheimer's Association, an estimated 6.7 million Americans aged 65 and older will have Alzheimer's in 2023, with projections reaching 12.7 million by 2050. This upward trend in neurological disorders is a significant driver for the induced pluripotent stem cell market.

Companies are actively seeking strategic partnerships and collaborations to expand their geographic reach and enhance product portfolios. Bristol Myers Squibb and Century Therapeutics, in January 2022, joined forces to develop iPSC-derived allogenic cell therapies targeting acute myeloid leukemia and multiple myeloma. Similarly, Evotec and Sernova announced a strategic partnership in May 2022 to develop iPSC-based beta cell replacement therapy for treating type 1 and type 2 diabetes.

Major players in the induced pluripotent stem cell market are intensifying their focus on introducing personalized induced pluripotent stem cells, exemplified by offerings such as Personal iPS. REPROCELL, a stem cell research company, launched Personal iPS in January 2021, providing a flexible and customizable service for reprogramming cells from various sources. The services include donor tissue collection, sample quarantine, derivation of primary cell lines, RNA-based iPSCs, and reprogramming technology.

In August 2021, catalant, a pharmaceutical company, acquired RheinCell Therapeutics GmbH, a move aimed at bolstering Catalent's presence in the cell and gene therapy sector and advancing therapies based on induced pluripotent stem cells. RheinCell Therapeutics GmbH, based in Germany, specializes in developing human induced pluripotent stem cells (iPSCs) for next-generation cell therapies.

Major companies operating in the induced pluripotent stem cell (ipsc) market report are FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc., Takara Bio, Inc., Lonza Group AG, Astellas Pharma Inc., ViaCyte, Inc., Ncardia, REPROCELL USA, Inc., Japan Tissue Engineering Co., Ltd., Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, Takaria Bio, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, MSD, Pfizer, Roche, Pharmasyntez, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, GlaxoSmithKline, Parexel, Bayer, Fate Therapeutics, Athersys, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, VistaGen Therapeutics, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Banco de Cordon del Peru, CryoHoldco, CellSave Arabia, Life Cell, AmiCare, Cells4life, ReeLabs, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart

North America was the largest region in the induced pluripotent stem cell (iPSC) market in 2023. Western Europe was the second largest region in the global induced pluripotent stem cell (iPSC) market share. The regions covered in the induced pluripotent stem cell (ipsc) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the induced pluripotent stem cell (ipsc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Induced Pluripotent Stem Cell (iPSC) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on induced pluripotent stem cell (ipsc) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for induced pluripotent stem cell (ipsc)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The induced pluripotent stem cell (ipsc) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Derived Cell Type: Hepatocytes; Fibroblasts; Keratinocytes; Amniotic Cells; Other Derived Cell Types
  • 2) By Application: Academic Research; Drug Discovery And Toxicity Studies; Regenerative Medicine; Cell And Gene Therapy
  • 3) By End-User: Hospitals; Research Laboratories
  • Companies Mentioned: FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc); Thermo Fisher Scientific, Inc; Takara Bio, Inc; Lonza Group AG; Astellas Pharma Inc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Induced Pluripotent Stem Cell (iPSC) Market Characteristics

3. Induced Pluripotent Stem Cell (iPSC) Market Trends And Strategies

4. Induced Pluripotent Stem Cell (iPSC) Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Induced Pluripotent Stem Cell (iPSC) Market Size and Growth

  • 5.1. Global Induced Pluripotent Stem Cell (iPSC) Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Induced Pluripotent Stem Cell (iPSC) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Induced Pluripotent Stem Cell (iPSC) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Induced Pluripotent Stem Cell (iPSC) Market Segmentation

  • 6.1. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hepatocytes
  • Fibroblasts
  • Keratinocytes
  • Amniotic Cells
  • Other Derived Cells
  • 6.2. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Academic Research
  • Drug Development And Discovery
  • Toxicity Screening
  • Regenerative Medicine
  • 6.3. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Research Laboratories

7. Induced Pluripotent Stem Cell (iPSC) Market Regional And Country Analysis

  • 7.1. Global Induced Pluripotent Stem Cell (iPSC) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Induced Pluripotent Stem Cell (iPSC) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market

  • 8.1. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Induced Pluripotent Stem Cell (iPSC) Market

  • 9.1. China Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 9.2. China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Induced Pluripotent Stem Cell (iPSC) Market

  • 10.1. India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Induced Pluripotent Stem Cell (iPSC) Market

  • 11.1. Japan Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 11.2. Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Induced Pluripotent Stem Cell (iPSC) Market

  • 12.1. Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Induced Pluripotent Stem Cell (iPSC) Market

  • 13.1. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Induced Pluripotent Stem Cell (iPSC) Market

  • 14.1. South Korea Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 14.2. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Induced Pluripotent Stem Cell (iPSC) Market

  • 15.1. Western Europe Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 15.2. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Induced Pluripotent Stem Cell (iPSC) Market

  • 16.1. UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Induced Pluripotent Stem Cell (iPSC) Market

  • 17.1. Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Induced Pluripotent Stem Cell (iPSC) Market

  • 18.1. France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Induced Pluripotent Stem Cell (iPSC) Market

  • 19.1. Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Induced Pluripotent Stem Cell (iPSC) Market

  • 20.1. Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market

  • 21.1. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 21.2. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Induced Pluripotent Stem Cell (iPSC) Market

  • 22.1. Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Induced Pluripotent Stem Cell (iPSC) Market

  • 23.1. North America Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 23.2. North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Induced Pluripotent Stem Cell (iPSC) Market

  • 24.1. USA Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 24.2. USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Induced Pluripotent Stem Cell (iPSC) Market

  • 25.1. Canada Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 25.2. Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Induced Pluripotent Stem Cell (iPSC) Market

  • 26.1. South America Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 26.2. South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Induced Pluripotent Stem Cell (iPSC) Market

  • 27.1. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Induced Pluripotent Stem Cell (iPSC) Market

  • 28.1. Middle East Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 28.2. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Induced Pluripotent Stem Cell (iPSC) Market

  • 29.1. Africa Induced Pluripotent Stem Cell (iPSC) Market Overview
  • 29.2. Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Induced Pluripotent Stem Cell (iPSC) Market Competitive Landscape And Company Profiles

  • 30.1. Induced Pluripotent Stem Cell (iPSC) Market Competitive Landscape
  • 30.2. Induced Pluripotent Stem Cell (iPSC) Market Company Profiles
    • 30.2.1. FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc)
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Thermo Fisher Scientific, Inc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Takara Bio, Inc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Lonza Group AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Astellas Pharma Inc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Induced Pluripotent Stem Cell (iPSC) Market Other Major And Innovative Companies

  • 31.1. ViaCyte, Inc
  • 31.2. Ncardia
  • 31.3. REPROCELL USA, Inc
  • 31.4. Japan Tissue Engineering Co., Ltd
  • 31.5. Merck KGaA
  • 31.6. Cynata Therapeutics Limited
  • 31.7. Dainippon Sumitomo Pharma
  • 31.8. Shenzhen Bioscience
  • 31.9. Shanghai Cell Therapy Group
  • 31.10. Car-T Bio
  • 31.11. JW therapeutics
  • 31.12. Fosun Kite Biotechnology
  • 31.13. Shanghai UniCar Therapy
  • 31.14. Takaria Bio
  • 31.15. SEED Biosciences SA

32. Global Induced Pluripotent Stem Cell (iPSC) Market Competitive Benchmarking

33. Global Induced Pluripotent Stem Cell (iPSC) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Induced Pluripotent Stem Cell (iPSC) Market

35. Induced Pluripotent Stem Cell (iPSC) Market Future Outlook and Potential Analysis

  • 35.1 Induced Pluripotent Stem Cell (iPSC) Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Induced Pluripotent Stem Cell (iPSC) Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Induced Pluripotent Stem Cell (iPSC) Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer